CB8025-21845: A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple CenterStudy To Evaluate The Safety, Tolerability, And Efficacy Of Seladelpar AdministeredFor 24 Weeks In Adult Subjects With Primary Sclerosing Cholangitis

Project: Research project

Project Details

Description

CB8025-21845: A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study To Evaluate The Safety, Tolerability, And Efficacy Of Seladelpar Administered For 24 Weeks In Adult Subjects With Primary Sclerosing Cholangitis
StatusActive
Effective start/end date1/29/207/30/20

Funding

  • CYMABAY THERAPEUTICS, INC

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.